Markov modelling of HIV infection evolution in the HAART era

Epidemiology and Infection

Volumn 137, Issue 9, 2009, Pages 1272-1282

  Binquet, C ^a,b,c   Le teuff, G ^a   Abrahamovicz, M ^d   Mahboubi, A ^c,e   Yazdanpanah, Y ^f   Rey, D ^g   Rabaud, C ^h   Chirouze, C ⁱ   Berger, J L ^j   Faller, J P ^k   Chavanet, P ^a   Quantin, C ^a   Piroth, Lionel ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d MCGILL UNIVERSITY   (Canada)

^e Chu   (France)

^f Department of Infectious Diseases   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j REIMS UNIVERSITY HOSPITAL   (France)

^k CHRU Belfort   (France)

more..

Author keywords

CD4 evolution; Disease progression; Highly active anti retroviral therapy (HAART); HIV; Multi state Markov model; Prognostic factors

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; POPULATION RESEARCH; PROBABILITY; PROGNOSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; VIRUS LOAD; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD; YOUNG ADULT;

EID: 69949112849     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268808001775     Document Type: Article

References (40)

1. Ho D. Time to hit HIV, early and hard. New England Journal of Medicine 1995; 333: 450-451.
2. BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-1092.
3. Carpenter C, et al. Antiretroviral therapy in adults: updated recommandations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283: 381-390.
4. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-316.
5. AIDS info. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services (http://AIDSinfo.nih.gov). Accessed 6 October 2005.
6. Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy, 2005. HIV Medicine 2005; 6 (Suppl. 2): 1-61.
7. Hammer S, et al. Treatment for adult HIV infection. 2006 recommandations of the international AIDS Society-USA Panel. Journal of the American Medical Association 2006; 296: 827-843.
8. Yeni P. Prise en charge medicale des personnes infectées par le VIH. Rapport 2006. Recommendations du Groupe d'Experts. Paris: Flammarion - Médecine - Sciences, 2006.
9. Egger M, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
10. Chene G, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective study. Lancet 2003; 362: 679-686.
11. Schechter MT, et al. Use of the Markov model to estimate the waiting times in a modified WHO staging system for HIV infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995; 8: 474-479.
12. Hendriks JC, et al. Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model. International Journal of Epidemiology 2000; 29: 565-572.
13. Kousignian I, et al. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 2003; 34: 50-57.
14. Alioum A, et al. Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Epidemiology 1998; 9: 605-612.
15. Dancourt V, et al. Modeling recurrence in colo-rectal cancer. Journal of Clinical Epidemiology 2004; 57: 243-251.
16. Alioum A, Commenges D. MKVPCI: A computer program for Markov models with piecewise constant intensities and covariates. Computer Methods and Programs in Biomedicine 2001; 64: 109-119.
17. Cox D. Regression models and life tables. Journal of the Royal Statistical Society 1972; B34: 187-220.
18. Marshall G, Guo W, Jones R. MARKOV: A computer program for multi-state Markov models with covariates. Computer Methods and Programs in Biomedicine 1995; 47: 147-156.
19. Yeni P, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommandations of internation AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288: 222-235.
20. Sypsa V, et al. Comparison of smoothing techniques for CD4 data in a Markov model with states defined by CD4: An example on the estimation of the HIV incubation time distribution. Statistics in Medicine 2001; 20: 3667-3676.
21. Dancourt V, et al. Modeling recurrence in colorectal cancer. Journal of Clinical Epidemiology 2004; 57: 243-251.
22. Rizzardi G, Lazzarin A, Pantaleo G. Potential role of immune modulation in the effective long-term control of HIV-1 infection. Journal of Biological Regulators and Homeostatic Agents 2002; 16 83-90.
23. Hughes M, et al. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. Journal of Infectious Diseases 1994; 169: 28-36.
24. Satten G, Longini I. Markov chains with measurement error: estimating the true course of a marker of the progression of human immunodeficiency virus disease. Applied Statistics 1996; 45: 275-309.
25. Arici C, et al. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. International Journal of STD AIDS 2001; 12: 573-581.
26. Nicastri E, et al. Gender differences in clinical progression of HIV-1 infected individuals during long-term highly active antiretroviral therapy. AIDS 2005; 19: 577-583.
27. Sterne J, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005; 366: 378-384.
28. Wheeler D, et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Bein Community Programs for Clinical Research on AIDS. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1998; 18: 80-85.
29. Wheeler D. Weight loss and disease progression in HIV infections. AIDS Read 1999; 9: 345-353.
30. Tang A, et al. Increasing risk of 5% or greated uni-ententional weight loss in a cohort of HIV-infected patients, 1995 to 2003. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 2005; 40: 70-76.
31. Binquet C, et al. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: The Aquitaine Cohort, 1996-1997. American Journal of Epidemiology 2001; 153: 386-393.
32. Thiebaut R, et al. Time-updates CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1 infected patients treated with a highly active antiretroviral therapy: The Aquitaine cohort, 1996-2001. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 2003; 33: 380-386.
33. Konopnicki D, et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
34. Rockstroh J, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. Journal of Infectious Diseases 2005; 192: 992-1002.
35. Salmon-Ceron D, et al. Liver disease as a major cause of death among HIV infected patients: Role of hepatitis C and B viruses and alcohol. Journal of Hepatology 2005; 42: 799-805.
36. Gebo K, Diener-West M, Moore R. Hospitalization rates differ by hepatitis C satus in an urban HIV cohort. Journal of Acquired Immune Deficiency Syndrome 2003; 34: 165-173.
37. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. Journal of Acquired Immune Deficiency Syndrome 2007; 46: 72-77.
38. Mocroft A, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: An observational cohort study. Lancet 2007; 370: 407-413.
39. 3 or greater. Journal of Acquired Immune Deficiency Syndrome 2007; 45: 183-192.
40. Tebas P, et al. Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. AIDS 2001; 15: 591-599.